Related Experiment Video
Updated: Apr 13, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
Published on: January 8, 2020
Mispricing in the medicare advantage risk adjustment model
Jing Chen1, Randall P Ellis2, Katherine H Toro3
1EMC Corporation, Hopkinton, MA, USA jchenstat@gmail.com.
The Centers for Medicare and Medicaid Services (CMS) payment models misprice healthcare costs for Medicare Advantage (MA) plans. Using more comprehensive Diagnostic Cost Group (DxCG) models reveals significant underpayments for sicker patients.
Area of Science:
- Health Economics
- Health Services Research
- Medical Informatics
Background:
- The Centers for Medicare and Medicaid Services (CMS) uses Hierarchical Condition Category (HCC) models to adjust payments for Medicare Advantage (MA) plans.
- These models aim to reflect enrollees' expected healthcare costs.
- Previous CMS models were simplified due to concerns about data submission burdens from health plans.
Purpose of the Study:
- To identify mispricing errors in CMS's HCC models for Medicare Advantage payments.
- To compare the accuracy of CMS models with more comprehensive Diagnostic Cost Group (DxCG) Medicare models.
- To evaluate the impact of model simplification on payment accuracy and predictive power.
Main Methods:
- Utilized Verisk Health's DxCG Medicare models, a refined version of the HCC framework with 189 clinical categories.
- Applied both CMS and DxCG models to Medicare's 2010-2011 fee-for-service 5% sample data.
- Analyzed discrepancies in predicted versus actual healthcare costs, particularly for patients with complex conditions.
Main Results:
- Identified two key mispricing errors in the CMS implementation: ignoring new enrollee data and using simplified models.
- CMS models recognized only 79 condition categories, excluding many diagnoses and merging heterogeneous conditions.
- In 2010, 13% of beneficiaries with higher-cost DxCG-recognized conditions had no CMS-recognized condition, leading to average underpayments of over one-third ($6628 in 2011).
Conclusions:
- The current CMS HCC model implementation results in significant mispricing and lower predictive accuracy compared to DxCG models.
- Simplified CMS models fail to adequately capture the costs associated with complex patient populations.
- CMS should consider adopting more refined, DxCG-like models, especially as MA plans now provide encounter data.
Related Concept Videos
Relative Risk
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Methods of Documentation VI: Case Management Model
For example, a patient with a chronic...
Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
Mismatch Repair

